Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose (Expansion Phase).

Sarah Cannon Research Institute
 (5.4 away) Contact site
  • 0 views
  • 16 May, 2021
  • +10 other locations
A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-585, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more prior lines of therapy. The study consists of 2 parts, a …

Florida Cancer Specialists
 (5.4 away) Contact site
  • 0 views
  • 26 May, 2021
  • +2 other locations
Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to …

antiandrogen therapy
tumor cells
external beam radiation therapy
cancer vaccine
androgens
21st Century Oncology
 (2.6 away) Contact site
  • 1420 views
  • 02 Jun, 2021
  • +78 other locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Florida Cancer Specialists
 (5.4 away) Contact site
  • 4293 views
  • 27 May, 2021
  • +497 other locations
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function Including Balance and Daily Activity in Patients With Castration-resistant Prostate Cancer (CRPC)

Researchers in this study want to compare the effects of drug darolutamide and drug enzalutamide on physical function, including balance and daily activity, in patients with castration-resistant prostate cancer (CRPC). Both darolutamide and enzalutamide are approved AR inhibitors used for the treatment of patients with CRPC. AR inhibitor is a …

Manatee Medical Research Institute
 (8.8 away) Contact site
  • 9 views
  • 04 Jun, 2021
  • +16 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Florida Cancer Specialists South
 (4.8 away) Contact site
  • 40 views
  • 13 May, 2021
  • +35 other locations
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

castration-resistant prostate cancer
testosterone
orchiectomy
luteinizing hormone
cancer
Florida Cancer Specialists
 (4.8 away) Contact site
  • 0 views
  • 15 May, 2021
  • +5 other locations
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris Testing

This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.

Manatee Medical Research Institute
 (9.2 away) Contact site
  • 0 views
  • 28 Mar, 2021
  • +5 other locations